The use of drug combinations to increase the effect of treatment is supported by multiple successes from in vitro and clinical cancer research, with dual inhibition of MAPK-ERK pathway components (Khunger et al., 2018), and combined inhibition of MEK and components of the PI3K signaling pathway being some of the most prominent examples (Jokinen and Koivunen, 2015; Arend et al., 2020). This evidence concerns the gene PIK3CA and cancer.